1.Lunn MR, Wang CH. Spinal muscular atrophy. Lancet. 2008;371:2120–33.
2.Sheng-Yuan Z, Xiong F, Chen YJ, et al. Molecular characterization of SMN copy number derived from carrier screening and from core families with SMA in a Chinese population. Eur J Hum Genet. 2010;18:978–84.
3.Kolb S J, Kissel J T. Spinal muscular atrophy. Neurol Clin. 2015;33:831–46.
4.Ottesen EW. ISS-N1 makes the First FDA-approved Drug for Spinal Muscular Atrophy. Transl Neurosci. 2017;8:1–6.
5.Prior TW, Nagan N. Spinal Muscular Atrophy: Overview of Molecular Diagnostic Approaches. Curr Protoc Hum Genet. 2016;88:9–27.
6.Wirth B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat. 2000;15:228–37.
7.Stabley DL, Harris AW, Holbrook J, et al. SMN1 and SMN2 copy numbers in cell lines derived from patients with spinal muscular atrophy as measured by array digital PCR. Mol Genet Genomic Med. 2015;3:248–57.
8.Zabnenkova VV, Dadali EL, Artemieva SB, Sharkova IV, Rudenskaya GE, Polyakov AV. SMN1 gene point mutations in type I–IV proximal spinal muscular atrophy patients with a single copy of SMN1. Genetika. 2015;51:1075–82.
9.He J, Zhang QJ, Lin QF, et al. Molecular analysis of SMN1, SMN2, NAIP, GTF2H2, and H4F5 genes in 157 Chinese patients with spinal muscular atrophy. Gene. 2013;518:325–9.
10.Zeng G, Zheng H, Cheng J, et al. Analysis and carrier screening for copy numbers of SMN and NAIP genes in children with spinal muscular atrophy. Chinese J Med Genet. 2014;31:152–5.
11.Zhidai Liu, Penghui Zhang, Xiaoyan He, et al. New Multiplex real-time PCR approach to detect gene mutations for spinal muscular atrophy. BMC Neurology. 2016, 16:141.
12.Jayesh Sheth, Mehui Mistri, Riddhi Bhavsar, et al. Batten disease: biochemical and molecular characterization revealing novel PPT1 and TPP1 gene mutations in Indian patients. BMC Neurology. 2018, 18:203.
13.Xi Chen, Yusheng Tong, Zhifeng Shi, et al. Noninvasive molecular diagnosis of craniopharvngioma with MRI-based radiomics approach. BMC Neurology. 2019, 19:6.
14.Ganji H, Nouri N, Salehi M, et al. Detection of intragenic SMN1 mutations in spinal muscular atrophy patients with a single copy of SMN1. J Child Neurol. 2015;30:558–62.
15.Yamamoto T, Sato H, Lai PS, et al. Intragenic mutations in SMN1 may contribute more significantly to clinical severity than SMN2 copy numbers in some spinal muscular atrophy (SMA) patients. Brain Dev. 2014;36:914–20.
16.Ronchi D, Previtali SC, Sora MG, et al. Novel splice-site mutation in SMN1 associated with a very severe SMA-I phenotype. J Mol Neurosci. 2015;56:212–5.
17.Ar Rochmah M, Awano H, Awaya T, et al. Spinal muscular atrophy carriers with two SMN1 copies. Brain Dev. 2017;39:851–60.
18.Govindaraj V, Rao AJ. Proteomic identification of non-erythrocytic alpha-spectrin–1 down-regulation in the pre-optic area of neonatally estradiol–17beta treated female adult rats. Horm Mol Biol Clin Investig. 2016;26:165–72.
19.Speicher DW. Structural and functional features of the alpha–1 domain from human erythrocyte spectrin. Prog Clin Biol Res. 1984;165:441–56.
20.Niss O, Chonat S, Dagaonkar N, et al. Genotype-phenotype correlations in hereditary elliptocytosis and hereditary pyropoikilocytosis. Blood Cells Mol Dis. 2016;61:4–9.
21.Han E, Kim A, Park J, et al. Spectrin Tunis (Sp alpha (I/78)) in a Korean family with hereditary elliptocytosis. Ann Lab Med. 2013;33:386–9.
22.Weston BW, Nair RP, Larsen RD, Lowe JB. Isolation of a novel human alpha (1,3)fucosyltransferase gene and molecular comparison to the human Lewis blood group alpha (1,3/1,4)fucosyltransferase gene. Syntenic, homologous, nonallelic genes encoding enzymes with distinct acceptor substrate specificities. J Biol Chem. 1992;267:4152–60.
23.Padro M, Cobler L, Garrido M, de Bolos C. Down-regulation of FUT3 and FUT5 by shRNA alters Lewis antigens expression and reduces the adhesion capacities of gastric cancer cells. Biochim Biophys Acta. 2011;1810:1141–9.
24.Inaba Y, Ohyama C, Kato T, et al. Gene transfer of alpha1,3-fucosyltransferase increases tumor growth of the PC–3 human prostate cancer cell line through enhanced adhesion to prostatic stromal cells. Int J Cancer. 2003;107:949–57.
25.Morscher RJ, Grunert SC, Burer C, et al. A single mutation in MCCC1 or MCCC2 as a potential cause of positive screening for 3-methylcrotonyl-CoA carboxylase deficiency. Mol Genet Metab. 2012;105:602–6.
26.Nguyen KV, Naviaux RK, Patra S, Barshop BA, Nyhan WL. Novel mutations in the human MCCA and MCCB gene causing methylcrotonylglycinuria. Mol Genet Metab. 2011;102:218–21.
27.Theodorou L, Nicolaou P, Koutsou P, et al. Genetic findings of Cypriot spinal muscular atrophy patients. Neurol Sci. 2015;36:1829–34.